Nextplat Stock Earnings Reports

NextPlat reported continued progress from its turnaround efforts in Q1 2026. The company completed a reverse stock split to regain Nasdaq compliance and says the turnaround is largely complete, shifting focus to scaling the business and expanding healthcare operations nationwide. Key financials: total net revenue of ~$10M (down year-over-year), consolidated gross profit of ~$3.4M and a consolidated gross margin of ~35% (up from ~21% YoY and ~18% in Q4 2025). Pharmacy gross margin improved materially (pharmacy gross margin cited at ~39%), and the healthcare segment produced positive segment operating income (~$24k) for the quarter. Operating loss narrowed to ~$1.1M versus larger losses previously. E‑commerce remained steady (~$3.2M) with growing IoT and government/enterprise pipeline. Balance sheet: cash of ~$11M, working capital of ~$14M, and no meaningful debt. Operational highlights include onboarding five new 340B pharmacy service agreements (expected to contribute in Q3 after ~90-day onboarding), average fulfillment of ~7,500 prescriptions/month for contracted facilities in Florida, a nationwide fulfillment partnership in development, and an e‑commerce healthcare site expected to launch before end of Q2. Management established an ATM program for optional financing flexibility but says there are no immediate plans to use it. The company expects continued margin expansion, reduced operating losses, and a path to operational profitability in the latter half of 2026, while pursuing selective inorganic and organic growth opportunities.